Judith Cave

Southampton, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

Graduates from widening participation medical programs are disadvantaged on residency selection.

Graduates from widening participation medical programs are disadvantaged on residency selection.

Journal: Medical teacher
Published: July 16, 2026

The temporal changes in GPT-4 performance on UKMLA practice questions: educational and clinical implications.

The temporal changes in GPT-4 performance on UKMLA practice questions: educational and clinical implications.

Journal: Frontiers in medicine
Published: May 22, 2026

Human lungs maintain tissue-resident memory T cells against a broad spectrum of pathogens.

Human lungs maintain tissue-resident memory T cells against a broad spectrum of pathogens.

Journal: Nature immunology
Published: May 13, 2026

Tissue-resident immune cells drive genetic risk in autoimmune and lung diseases.

Tissue-resident immune cells drive genetic risk in autoimmune and lung diseases.

Journal: Nature immunology
Published: July 22, 2025

Evolutionary characterization of lung cancer metastasis.

Evolutionary characterization of lung cancer metastasis.

Journal: Nature
Published: June 29, 2025

Offering peer coaching to hospital consultants is supportive and cost effective.

Offering peer coaching to hospital consultants is supportive and cost effective.

Journal: Future healthcare journal
Published: November 04, 2024

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.

Journal: NPJ precision oncology
Published: July 30, 2024

Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx.

Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx.

Journal: Nature
Published: July 04, 2024

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres.

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres.

Journal: BMJ open
Published: November 22, 2023

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.

Journal: EClinicalMedicine
Published: March 27, 2023

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis.

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis.

Journal: Frontiers in oncology
Published: February 11, 2023

The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study.

The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study.

Journal: International journal of molecular sciences
Published: November 26, 2022
Showing 1-12 of 34

Last Updated: 09/26/2026